Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Posted on July 7, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI, Small Cap News | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

Posted on July 6, 2020 by MissionIR

Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc. Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins The companies were acquired … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise

Posted on June 30, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday announced the closing of its previously announced transaction. According to the update, Predictive Oncology secured approximately $2.2 million in … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Leverages Unique Patient-Derived Platform to Assist Oncologists

Posted on June 26, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is providing clinical decision support tools to support oncologists in personalizing cancer treatment. A recent article discussing the company further reads, “Through its unique patient derived (PDx) platform, which tests the drug … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media

Posted on June 18, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update

Posted on June 9, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain steadfast in … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

Posted on June 4, 2020 by MissionIR

POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.

Posted on June 3, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

Posted on June 2, 2020 by MissionIR

POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes

Posted on June 1, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment